Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments

References

• National Cancer InstituteCancer of the prostate. SEER Sata Fact Sheets Available at: http://seer.cancer.gov/statfacts/html/prost.htmlAccessed June 3, 2011
   Google Scholar
• GuralnikJMLaCroixAZEverettDFAging in the eighties: the prevalence of comorbidity and its association with disabilityAdvance Data17019898 Publication No. PHS 89–1250
   Google Scholar
• YancikRCancer burden in the aged: an epidemiologic and demographic overviewCancer1997807127312839317180
   PubMed Web of Science ®Google Scholar
• KattanMWWheelerTMScardinoPTPostoperative nomogram for disease recurrence after radical prostatectomy for prostate cancerJ Clin Oncol19991751499150710334537
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardECancer statisticsCA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar
• PowellIJEpidemiology and pathophysiology of prostate cancer in African-American menJ Urol2007177244444917222606
   PubMed Web of Science ®Google Scholar
• ParisPLKupelianPAHallJMAssociation between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patientsCancer Epidemiol Biomarkers Prev199981090190510548319
   PubMed Web of Science ®Google Scholar
• WiltTJMacDonaldRRutksIShamliyanTATaylorBCKaneRLSystematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancerAnn Intern Med2008148643544818252677
   PubMed Web of Science ®Google Scholar
• ZeliadtSBRamseySDPensonDFWhy do men choose one treatment over another?: a review of patient decision making for localized prostate cancerCancer200610691865187416568450
   PubMed Web of Science ®Google Scholar
• FowlerFJJrMcNaughton CollinsMAlbertsenPCComparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancerJAMA2000283243217322210866869
   PubMed Web of Science ®Google Scholar
• TolisGAckmanDStellosATumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonistsProc Natl Acad Sci U S A1982795165816626461861
   PubMed Web of Science ®Google Scholar
• KlotzLBoccon-GibodLShoreNDThe efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerBJU Int2008102111531153819035858
   PubMed Web of Science ®Google Scholar
• ShoreNDMoulJWCrawfordEProstate-specific antigen (PSA) progression-free survival (PFS): a comparison of degarelix versus leuprolide in patients with prostate cancerJ Clin OncolGenitourinary Cancers Symposium201129Suppl 7 Abstr 12
   Google Scholar
• van AndelGKurthKHThe impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancerEur Urol200344220921412875940
   PubMed Web of Science ®Google Scholar
• WilkeDRParkerCAndonowskiATestosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonistsBJU Int200697596396816542340
   PubMed Web of Science ®Google Scholar
• LoblawDAVirgoKSNamRInitial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineJ Clin Oncol200725121596160517404365
   PubMed Web of Science ®Google Scholar
• BalesGTChodakGWA controlled trial of bicalutamide versus castration in patients with advanced prostate cancerUrology199647Suppl 1A38438560677
   PubMed Web of Science ®Google Scholar
• KassoufWTanguaySAprikianAGNilutamide as second line hormone therapy for prostate cancer after androgen ablation failsJ Urol200316951742174412686822
   PubMed Web of Science ®Google Scholar
• WhitakerHCHanrahanSTottyNAndrogen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogensClin Cancer Res200410217392740115534116
   PubMed Web of Science ®Google Scholar
• AkakuraKBruchovskyNGoldenbergSLRenniePSBuckleyARSullivanLDEffects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigenCancer1993719278227907682149
   PubMed Web of Science ®Google Scholar
• Boccon-GibodLHammererPMadersbacherSMottetNPrayer- GalettiTTunnUThe role of intermittent androgen deprivation in prostate cancerBJU Int2007100473874317662079
   PubMed Web of Science ®Google Scholar
• KlotzLHHerrHWMorseMJWhitmoreWFIntermittent endocrine therapy for advanced prostate cancerCancer19865811254625502429759
   PubMed Web of Science ®Google Scholar
• GoldenbergSLBruchovskyNGleaveMEIntermittent androgen suppression in the treatment of prostate cancer: a preliminary reportUrology1995455839844 discussion 44–457538246
   PubMed Web of Science ®Google Scholar
• CrookJMSzumacherEMaloneSHuanSSegalRIntermittent androgen suppression in the management of prostate cancerUrology199953353053410096379
   PubMed Web of Science ®Google Scholar
• KlotzLO’CallaghanCJDingKA phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013J Clin Oncol201129Suppl 7 Abstr 3
   Web of Science ®Google Scholar
• TunnUEckartOKienleECan intermittent androgen deprivation be an alternative to continuous androgen withdrawal in patients with PSA relapse? First results of the randomized prospective phase III clinical trial EC 507J Urol2003169Suppl 41481a
   Web of Science ®Google Scholar
• SmallEJVogelzangNJSecond-line hormonal therapy for advanced prostate cancer: a shifting paradigmJ Clin Oncol19971513823888996165
   PubMed Web of Science ®Google Scholar
• SmallEJHalabiSDawsonNAAntiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)J Clin Oncol20042261025103315020604
   PubMed Web of Science ®Google Scholar
• NishimuraKNonomuraNYasunagaYLow doses of oral dexamethasone for hormone-refractory prostate carcinomaCancer200089122570257611135218
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• BertholdDRPondGRSobanFdeWitREisenbergerMTannockIFDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyJ Clin Oncol200826224224518182665
   PubMed Web of Science ®Google Scholar
• BerryWDakhilSModianoMGregurichMAsmarLPhase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancerJ Urol200216862439244312441935
   PubMed Web of Science ®Google Scholar
• TannockIFOsobaDStocklerMRChemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsJ Clin Oncol1996146175617648656243
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• KellyWKHalabiSCarducciMAA randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401J Clin Oncol201028Suppl 18LBA4511
   Web of Science ®Google Scholar
• SternbergCNPetrylakDPSartorOMultinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trialJ Clin Oncol200927325431543819805692
   PubMed Web of Science ®Google Scholar
• ScherHIBeerTMHiganoCSAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase1–2 studyLancet201037597241437144620398925
   PubMed Web of Science ®Google Scholar
• O’DonnellAJudsonIDowsettMHormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerBr J Cancer200490122317232515150570
   PubMed Web of Science ®Google Scholar
• PotterGABarrieSEJarmanMNovel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancerJ Med Chem19953813246324717608911
   PubMed Web of Science ®Google Scholar
• AttardGReidAHA’HernRSelective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerJ Clin Oncol200927233742374819470933
   PubMed Web of Science ®Google Scholar
• DanilaDCMorrisMJde BonoJSPhase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerJ Clin Oncol20102891496150120159814
   PubMed Web of Science ®Google Scholar
• ReidAHAttardGDanilaDCSignificant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateJ Clin Oncol20102891489149520159823
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCFizaziKAbiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled Phase III studyAnn Oncol201021LBA5
   Web of Science ®Google Scholar
• MolinaABelldegrunANovel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signalingJ Urol2011185378779421239012
   PubMed Web of Science ®Google Scholar
• BodeCJGuptaMLJrReiffEAEpothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubulesBiochemistry200241123870387411900528
   PubMed Web of Science ®Google Scholar
• LinAMRosenbergJEWeinbergVKClinical outcome of taxane resistant hormone refractory prostate cancer patients treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP))Proc Am Soc Clin Oncol200624Suppl231s
   Google Scholar
• DrakeCGAntonarakisESUpdate: immunological strategies for prostate cancerCurr Urol Rep201011320220720425628
   PubMedGoogle Scholar
• MoonCParkJCChaeYKYunJHKimSCurrent status of experimental therapeutics for prostate cancerCancer Lett2008266211613418440696
   PubMed Web of Science ®Google Scholar
• WangXYuJSreekumarAAutoantibody signatures in prostate cancerN Engl J Med2005353121224123516177248
   PubMed Web of Science ®Google Scholar
• PalenaCSchlomJVaccines against human carcinomas: strategies to improve antitumor immune responsesJ Biomed Biotechnol2010201038069720300434
   PubMedGoogle Scholar
• BanchereauJSteinmanRMDendritic cells and the control of immunityNature199839266732452529521319
   PubMed Web of Science ®Google Scholar
• FishmanMA changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancerExpert Opin Biol Ther20099121565157519916735
   PubMed Web of Science ®Google Scholar
• ZhangHMelamedJWeiPConcordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancerCancer Immun20033212747744
   PubMedGoogle Scholar
• SandaMGRestifoNPWalshJCMolecular characterization of defective antigen processing in human prostate cancerJ Natl Cancer Inst19958742802857707419
   PubMed Web of Science ®Google Scholar
• ZhangLGajewskiTFKlineJPD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia modelBlood200911481545155219417208
   PubMed Web of Science ®Google Scholar
• AhmadzadehMJohnsonLAHeemskerkBTumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood200911481537154419423728
   PubMed Web of Science ®Google Scholar
• ChappellDBRestifoNPT cell-tumor cell: a fatal interaction?Cancer Immunol Immunother199847265719769114
   PubMed Web of Science ®Google Scholar
• CurtiATrabanelliSSalvestriniVBaccaraniMLemoliRMThe role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematologyBlood2009113112394240119023117
   PubMed Web of Science ®Google Scholar
• FukumuraDKashiwagiSJainRKThe role of nitric oxide in tumour progressionNat Rev Cancer20066752153416794635
   PubMed Web of Science ®Google Scholar
• LahdenrantaJHagendoornJPaderaTPEndothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasisCancer Res20096972801280819318557
   PubMed Web of Science ®Google Scholar
• SmallEJFratesiPReeseDMImmunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cellsJ Clin Oncol200018233894390311099318
   PubMed Web of Science ®Google Scholar
• BanchereauJSteinmanRMDendritic cells and the control of immunityNature199839266732452529521319
   PubMed Web of Science ®Google Scholar
• BurchPABreenJKBucknerJCPriming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancerClin Cancer Res2000662175218210873066
   PubMed Web of Science ®Google Scholar
• HsuFJBenikeCFagnoniFVaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cellsNat Med19962152588564842
   PubMed Web of Science ®Google Scholar
• NestleFOAlijagicSGillietMVaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cellsNat Med1998433283329500607
   PubMed Web of Science ®Google Scholar
• CarballidoEFishmanMSipuleucel-T. Prototype for Development of Anti-tumor VaccinesCurr Oncol Rep201113211211921243538
   PubMed Web of Science ®Google Scholar
• FinnOJCancer vaccines: between the idea and the realityNat Rev Immunol20033863064112974478
   PubMed Web of Science ®Google Scholar
• MillerRAChrispCT cell subset patterns that predict resistance to spontaneous lymphoma, mammary adenocarcinoma, and fibrosarcoma in miceJ Immunol200216931619162512133992
   PubMed Web of Science ®Google Scholar
• KapasiZFMurali-KrishnaKMcRaeMLAhmedRDefective generation but normal maintenance of memory T cells in old miceEur J Immunol20023261567157312115639
   PubMed Web of Science ®Google Scholar
• SmallEJSchellhammerPFHiganoCSPlacebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerJ Clin Oncol200624193089309416809734
   PubMed Web of Science ®Google Scholar
• BubleyGJCarducciMDahutWEligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupJ Clin Oncol199917113461346710550143
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• Dendreon company: product information Available at: www.provenge.comAccessed June 3, 2011
   Google Scholar
• StewartFPdela RosaCPSheikhNACorrelation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancerJ Clin Oncol201028Suppl 15 Abst 4552
   Web of Science ®Google Scholar
• BeerTMRyanCWVennerPMDouble-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsJ Clin Oncol200725666967417308271
   PubMed Web of Science ®Google Scholar
• HiganoCSSchellhammerPFSmallEJIntegrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCancer2009115163670367919536890
   PubMed Web of Science ®Google Scholar
• ZhuMTerasawaHGulleyJEnhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cellsCancer Res20016193725373411325845
   PubMed Web of Science ®Google Scholar
• GulleyJLToddNDahutWSchlomJArlenPA phase II study of PROSTVAC-VF vaccine, and the role of GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC)J Clin OncolASCO Annual Meeting Proceedings200523Suppl 16 Pt I Abst 2504
   Google Scholar
• SteinWDGulleyJLSchlomJTumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic EfficacyClin Cancer Res201117490791721106727
   PubMed Web of Science ®Google Scholar
• GulleyJLArlenPMTsangKYPilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaClin Cancer Res200814103060306918483372
   PubMed Web of Science ®Google Scholar
• SanghaRNorthSL-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancerExpert Opin Biol Ther20077111723173017961094
   PubMed Web of Science ®Google Scholar
• LubaroffDMKonetyBRLinkBPhase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic resultsClin Cancer Res200915237375738019920098
   PubMed Web of Science ®Google Scholar
• ChangSSReuterVEHestonWDFive different anti-prostate- specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculatureCancer Res199959133192319810397265
   PubMed Web of Science ®Google Scholar
• BaccalaASerciaLLiJExpression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasmsUrology200770238539017826525
   PubMed Web of Science ®Google Scholar
• Elsässer-BeileUBühlerPWolfPTargeted therapies for prostate cancer against the prostate specific membrane antigenCurr Drug Targets200910211812519199907
   PubMed Web of Science ®Google Scholar
• TjoaBALodgePASalgallerMLBoyntonALMurphyGPDendritic cell-based immunotherapy for prostate cancerCA Cancer J Clin19994921171286511198886
   PubMed Web of Science ®Google Scholar
• WheelerTMZhaoBSonpavdeGAntigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC)J Clin Oncol201129Suppl 7 Abstr 176
   Web of Science ®Google Scholar
• SheuBCHsuSMHoHNLienHCHuangSCLinRHA novel role of metalloproteinase in cancer-mediated immunosuppressionCancer Res200161123724211196168
   PubMed Web of Science ®Google Scholar
• SmallEJSacksNNemunaitisJGranulocyte macrophage colony-stimulating factor – secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancerClin Cancer Res200713133883389117606721
   PubMed Web of Science ®Google Scholar
• HiganoCSCormanJMSmithDCPhase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCancer2008113597598418646045
   PubMed Web of Science ®Google Scholar
• SimonsJWCarducciMAMikhakBPhase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancerClin Cancer Res20061211 Pt 13394340116740763
   PubMed Web of Science ®Google Scholar
• Cell Genesys Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=98399&p=irol-newsArticle&ID=1191052Accessed June 3, 2011
   Google Scholar
• O’DaySHodiFSMcDermottDFA phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanomaJ Clin Oncol2010 ASCO Annual Meeting Proceedings201028Suppl 18 Abst 4
   Google Scholar
• TarhiniALoEMinorDRReleasing the brake on the immune system: ipilimumab in melanoma and other tumorsCancer Biother Radiopharm201025660161321204754
   PubMed Web of Science ®Google Scholar
• CooperbergMRHinotsuSNamikiMRisk assessment among prostate cancer patients receiving primary androgen deprivation therapyJ Clin Oncol200927264306431319667269
   PubMed Web of Science ®Google Scholar
• ScherHIHalabiSTannockIProstate Cancer Clinical Trials Working GroupDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol20082671148115918309951
   PubMed Web of Science ®Google Scholar
• ChambersJDNeumannPJListening to Provenge – what a costly cancer treatment says about future Medicare policyN Engl J Med2011364181687168921470004
   PubMed Web of Science ®Google Scholar
• PetrylakDPDawsonNAGardnerTPersistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studiesJ Clin Oncol2010 ASCO Annual Meeting Proceedings201028Suppl 15 Abst 4551
   Google Scholar